Form 13-F position report

AVROBIO INC COM (DE)

Reported by GMT CAPITAL CORP

AVRO CUSIP 05455M100 Manager CIK 0001106191

Reported 3,494,490 shares, up 899,576 (34.7%) from the prior quarter.

Reported value -6.1%; share count 34.7% vs. the prior quarter.

Added
% of reported 13F value 0.2% This manager · Q2 2022
Shares 3,494,490 Quarter-end amount reported
Reported value $3,215,000 Fair value at quarter end
Consecutive quarters held 6 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 11903000
2021-12-31 9990000
2022-03-31 3425000
2022-06-30 3215000
2022-09-30 2245000
2022-12-31 2359598
2023-03-31 4357859
2023-06-30 2291655
2023-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

9 quarters
Quarterly reported position history for AVROBIO INC COM (DE) held by GMT CAPITAL CORP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2023 Reduced 0 -2,412,015 (-100.0%) 0 $0 2023-11-13
Q2 2023 Reduced 2,412,015 -1,945,844 (-44.7%) 0.09% $2,291,655 2023-08-10
Q1 2023 Added 4,357,859 +1,048,000 (31.7%) 0.17% $4,357,859 2023-05-09
Q4 2022 Reduced 3,309,859 -184,631 (-5.3%) 0.11% $2,359,598 2023-02-03
Q3 2022 Unchanged 3,494,490 0 (0.0%) 0.14% $2,245,000 2022-11-10
Q2 2022 Added 3,494,490 +899,576 (34.7%) 0.2% $3,215,000 2022-08-10
Q1 2022 Unchanged 2,594,914 0 (0.0%) 0.22% $3,425,000 2022-05-11
Q4 2021 Added 2,594,914 +461,700 (21.6%) 0.77% $9,990,000 2022-02-11
Q3 2021 Unchanged 2,133,214 0 (0.0%) 1.05% $11,903,000 2021-11-09
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

93 managers reported AVROBIO INC COM (DE) for Q2 2022.

Managers reporting AVROBIO INC COM (DE) in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Atlas Venture Life Science Advisors LLC Unchanged 4,520,863 0 0.7% $4,159,000 3 qtrs
GMT CAPITAL CORP This report Added 3,494,490 +899,576 0.2% $3,215,000 6 qtrs
JPMorgan Chase & Co Added 2,120,044 +125,653 < 0.01% $1,950,000 17 qtrs
BlackRock Inc Reduced 2,000,247 -1,787,867 < 0.01% $1,841,000 17 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 1,555,800 +670,700 < 0.01% $1,431,000 9 qtrs
ACADIAN ASSET MANAGEMENT LLC Added 1,123,564 +210,107 < 0.01% $1,033,000 4 qtrs
K2 PRINCIPAL FUND L P New 1,115,177 +1,115,177 0.11% $1,026,000 1 qtr
VANGUARD GROUP INC Reduced 1,020,487 -52,681 < 0.01% $939,000 17 qtrs
Aisling Capital Management LP Unchanged 1,009,779 0 0.66% $929,000 15 qtrs
MILLENNIUM MANAGEMENT LLC Added 794,522 +270,083 < 0.01% $731,000 13 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 10, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
3,494,490
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.